€153.03
1.11% today
L&S, Jul 01, 12:00 pm CET
ISIN
DE0006599905
Symbol
MRK
Index
Sector
Industry

Merck Share price

€154.75
-12.90 7.69% 1M
+12.20 8.56% 6M
+10.65 7.39% YTD
+4.25 2.82% 1Y
-4.85 3.04% 3Y
+62.75 68.21% 5Y
+91.36 144.12% 10Y
Xetra, Closing price Fri, Jun 28 2024
ISIN
DE0006599905
Symbol
MRK
Index
Sector
Industry

Key figures

Market capitalization €67.28b
Enterprise Value €75.09b
PER (TTM) P/E ratio 24.71
EV/FCF (TTM) EV/FCF 34.01
EV/Sales (TTM) EV/Sales 3.61
P/S ratio (TTM) P/S ratio 3.23
P/B ratio (TTM) P/B ratio 2.40
Dividend yield 1.42%
Last dividend (FY23) €2.20
Sales growth (TTM) Sales growth -6.75%
Turnover (TTM) Turnover €20.82b
EBIT (operating result TTM) EBIT €4.13b
Free cash flow (TTM) Free cash flow €2.21b
Cash position €2.22b
EPS (TTM) EPS €6.26
P/E ratio expected 22.54
P/S ratio expected 3.16
EV/Sales expected 3.53
Show more

Register now for free to activate an alarm for the Merck share.

Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.

Merck Share analysis

Analyst opinions

17 Analysts have issued a Merck forecast:

15x Buy
88%
2x Hold
12%

Analyst opinions

17 Analysts have issued a Merck forecast:

Buy
88%
Hold
12%

Financial data from Merck

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
20,820 20,820
7% 7%
100%
- Direct costs 8,739 8,739
3% 3%
42%
12,081 12,081
13% 13%
58%
- Selling and administrative expenses 3,649 3,649
5% 5%
18%
- Research and development costs 2,428 2,428
4% 4%
12%
6,004 6,004
19% 19%
29%
- Depreciation and amortization 1,878 1,878
2% 2%
9%
EBIT (operating result) EBIT 4,126 4,126
25% 25%
20%
Net profit 2,722 2,722
16% 16%
13%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the Merck share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Merck Share News

EQS
7 days ago
Darmstadt, 24. Juni 2024: Merck KGaA untersucht eine Behandlung mit Xevinapant in Kombination mit platinbasierter Chemotherapie (CRT) im Vergleich zu Placebo plus CRT bei Patienten mit nicht resezierten lokal fortgeschrittenen Kopf-Hals-Tumoren in einer Phase-III-Studie (TrilynX). Die Gesellschaf...
marktEINBLICKE
7 months ago
Für die Aktie von Merck KGaA kam es in den vergangenen Wochen knüppeldick. Im kommenden Jahr soll die Erholung angegangen werden.
EQS
7 months ago
Darmstadt, 5. Dezember 2023: Die Merck KGaA erforscht einen oralen, hochselektiven, das zentrale Nervensystem penetrierenden Inhibitor der Brutontyrosinkinase ("BTKi") als potenzielle Behandlung für schubförmige Multiple Sklerose ("RMS") in zwei zulassungsrelevanten klinischen Phase-III-Studien (...
More Merck News

Company profile

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and Performance Materials. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Head office Germany
CEO Belén López
Employees 62,908
Founded 1995
Website www.merckgroup.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now